Pérol M, Pavlakis N, Levchenko E, et al. - Considering the phase 3 ALEX study that demonstrated superior efficacy and safety profile of alectinib vs crizotinib in treatment-naïve ALK+ non-small-cell lung cancer, researchers sought to evaluate disease burden, treatment-related symptom tolerability, and health-related quality of life with alectinib vs crizotinib via reporting on patient-reported outcomes (PROs) from ALEX. Either alectinib 600 mg or crizotinib 250 mg was administered to patients twice daily until disease progression, death, or withdrawal. They used EORTC QLQ-C30 and LC13 questionnaires to obtain PRO data. They standardized raw scores to a 0–100-point range; a ≥ 10-point score change was defined as clinically meaningful. Time to deterioration was defined as the time from randomization until confirmed clinically meaningful deterioration (ie, a ≥ 10-point score change from baseline). Outcomes revealed prolongation of QoL and lung cancer symptom improvement with alectinib vs crizotinib. Alectinib was correlated with better patient-reported tolerability on treatment-related symptoms. PRO outcomes thereby confirm the superior efficacy and tolerability of alectinib vs crizotinib demonstrated in the ALEX study.